MMRC Horizon One: RRMM (MMRC-099) (NCT06171685)
MMRC Horizon One: A Phase II Randomized Adaptive Platform Trial Evaluating Novel Therapies in Relapsed or Refractory Multiple Myeloma (MMRC-099)
🩺 Plain-English Summary (8th-Grade Level)
This trial is an adaptive platform trial. The structure of the protocol allows the trial to evolve over time. Multiple investigational arms will be included within the trial under a Master Protocol (MP). These investigational arms may be added as appendices at different times depending on whether they are trial-ready and whether accrual in the trial will support another arm. Accrual to an arm will terminate in accord with the arm's appendix to the Master Protocol. The purpose of this proposed structure is to support the recurrent research challenge of efficiently evaluating what is the best therapy for a particular patient.
Who can join: Review the eligibility criteria below.
Location: City of Hope — Duarte, California
Age range: 18 Years to 99 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (13 Sites)
- City of Hope — Duarte, California
- Emory Winship Cancer Center — Atlanta, Georgia
- University of Chicago Cancer Center — Chicago, Illinois
- Beth Israel Deaconess Medical Center — Boston, Massachusetts
- Dana Farber Cancer Institute/Harvard Medical School — Boston, Massachusetts
- Barbara Ann Karmanos Cancer Center — Detroit, Michigan
- Mayo Clinic Rochester — Rochester, Minnesota
- Washington University Medicine — St Louis, Missouri
- Hackensack University Medical Center — Hackensack, New Jersey
- Memorial Sloan Kettering Cancer Center — New York, New York
- Mt. Sinai School of Medicine — New York, New York
- Atrium Levine Cancer Institute — Charlotte, North Carolina
- Tennessee Oncology — Nashville, Tennessee
📞 Contact the Study Coordinator
Phone: (800) 826-4673
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Relapse Multiple Myeloma
- FT836 CAR T-cell Therapy in Combination With Daratumumab in Patients With Relapsed and/or Refractory Multiple Myeloma — Milwaukee, Wisconsin
- Cilta-Talq Fusion Study: A Phase 1b Study of Talquetamab Bridging Therapy Followed by Ciltacabtagene Autoleucel in Patients With Relapsed/Refractory Multiple Myeloma — Milwaukee, Wisconsin
- Study of Selinexor With Carfilzomib, Isatuximab and Dexamethasone for Patients With Relapsed and/or Refractory Multiple Myeloma — Madison, Wisconsin
Explore by condition: All Relapse Multiple Myeloma clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.